CHEST 2014; 146(6):1521-1530 e-Appendix 1. Double-dummy study blinding procedure A double-dummy design was used for the active-comparator studies because these studies included delivery with the ELLIPTA™ dry powder inhaler (DPI) and the HandiHaler™ DPI. Blister packaged capsules of tiotropium bromide (TIO) or its corresponding placebo were administered once daily in the morning via the HandiHaler DPI and FF/VI or placebo were administered once-daily in the morning via the ELLIPTA™ DPI. Each patient took one dose from the HandiHaler™ DPI and one dose from the ELLIPTA™ DPI each morning. Blinding of TIO was imperfect, however, because the TIO capsules had trade markings but the placebo capsules, while closely matched in color, did not have trade markings. Whether patients would notice, and rightly or wrongly attach any significance to the capsule markings, is unclear. As these studies were of parallel group design, the capsule type was consistent for each patient for the duration of the study. Both the TIO and placebo blister packages were covered with opaque over-labels with the intent of shielding information appearing on the blister packaging of TIO. The HandiHaler™ DPIs were covered with labels in order to mask identifying marks on the inhaler. Dosing in the clinic was administered without the presence of staff involved with safety and efficacy assessments to guard against the possibility that they would observe and draw correct inferences from the presence or absence of markings on capsules removed from the blisters.
Online Supplement
20 (15) 35 (14) 1 35 (28) 41 (32) 76 (30) 2 33 (26) 29 (22) 62 (24) >2 44 (35) 40 (31) 84 (33) Number of exacerbations in last 3 years that required hospitalisation 0 73 (57) 77 (59) 150 (58) 1 32 (25) 33 (25) 65 (25) 2 14 (11) 9 (7) 23 (9) >2 8 (6) 11 (8) 19 (7) Note: Number of COPD exacerbations reported in the 12 months prior to the Screening Visit.
In the 3 years prior to screening, 86% report having at least one moderate exacerbation (i.e., that required outpatient oral/systemic corticosteroids and/or antibiotics), 41% report having been hospitalized for an exacerbation. COPD=chronic obstructive pulmonary disease; FF=fluticasone furoate; TIO=tiotropium; VI=vilanterol
Online Supplement A responder is defined as a ≥1m/s reduction from baseline of aPWV at week 12. A non-responder is defined as a <1m/s reduction from baseline or missing of aPWV at week 12. Patients who withdrew before week 12 are counted as non-responders. If a patient had no post-baseline pulse wave velocity data collected then the response status is missing. A patient with one or more Cardiovascular history/risk factors recorded as a current or past medical condition at the screening/re-screening visit is considered to have cardiovascular history/risk factors. All results are taken at the screening/rescreening visit except baseline which is taken at pre-dose Day 1. For all labs baseline is pre-dose Day 1. For all vital signs endpoints baseline is pre-dose Day 1. ANC=absolute neutrophil count; aPVW=aortic pulse wave velocity; BP=blood pressure; FEV 1 =forced expiratory volume in 1 second; FVC=forced vital capacity; GI/L=10 9 cells/liter; IC=inspiratory capacity; SD=standard deviation a Data are mean (SD) b Baseline pre-bronchodilator measurement
